> Detailanzeige

Kim, Dennis (Dong Hwan); Hamad, Nada; Lee, Hong Gi; Kamel‐Reid, Suzanne; Lipton, Jeffrey H.

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase
  • Beteiligte: Kim, Dennis (Dong Hwan); Hamad, Nada; Lee, Hong Gi; Kamel‐Reid, Suzanne; Lipton, Jeffrey H.
  • Erschienen: Wiley, 2014
  • Erschienen in: American Journal of Hematology, 89 (2014) 6, Seite 626-632
  • Sprache: Englisch
  • DOI: 10.1002/ajh.23707
  • ISSN: 0361-8609; 1096-8652
  • Schlagwörter: Hematology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>It is unclear if patients with CML treated with imatinib who fail to achieve <jats:italic>BCR/ABL</jats:italic> transcript levels &lt;10%<jats:sup>IS</jats:sup> at 3 months i.e. an early molecular response (EMR) have a better prognosis if they achieve a response by 6 months. We reviewed 320 patients with chronic myeloid leukemia (CML) in chronic phase receiving Imatinib therapy with 3 and 6 month <jats:italic>BCR/ABL</jats:italic> transcript levels available, and divided them into four groups. Group I (achieved an EMR at 3 months), Group II (did not achieve an EMR at 3 months, but achieved a transcript level of &lt;1% at 6 months), Group III (did not achieve an EMR at 3 months, then at 6 months achieved a level between 1% and 10%) and Group IV (failed to achieve a response at 3 and 6 months). Compared to Group I, Group IV showed significantly worse freedom from treatment failure (FTF; 93.1% vs 69.0%, <jats:italic>P</jats:italic> &lt; 0.001), progression free survival (97.7% vs 77.3%, <jats:italic>P</jats:italic> &lt; 0.001) and overall survival (98.3% vs 78.9%, <jats:italic>P</jats:italic> &lt; 0.001). While, group III showed inferior PFS (98.3% vs 90.4%, <jats:italic>P</jats:italic> = 0.013) and OS (97.7% vs 90.4%, <jats:italic>P</jats:italic> = 0.037), but no difference in FTF (93.1% vs 92.0%, <jats:italic>P</jats:italic> = 0.520). There were no significant differences between Groups I and II. A <jats:italic>BCR/ABL</jats:italic> transcript level at 6 months can identify a “good‐risk” subgroup among patients who fail to achieve an EMR on Imatinib therapy for CML.Am. J. Hematol. 89:626–632, 2014. © 2014 Wiley Periodicals, Inc.</jats:p>
  • Zugangsstatus: Freier Zugang